CellaVision AB Stock price

Equities

CEVI

SE0000683484

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm 07:59:38 2024-03-28 am EDT 5-day change 1st Jan Change
239 SEK 0.00% Intraday chart for CellaVision AB +2.58% +12.74%
Sales 2023 677M 63.28M Sales 2024 * 782M 73.01M Capitalization 5.7B 533M
Net income 2023 130M 12.15M Net income 2024 * 174M 16.26M EV / Sales 2023 7.38 x
Net cash position 2023 56.94M 5.32M Net cash position 2024 * 117M 10.9M EV / Sales 2024 * 7.14 x
P/E ratio 2023
38.8 x
P/E ratio 2024 *
32.8 x
Employees -
Yield 2023
1.06%
Yield 2024 *
1.04%
Free-Float 61.96%
More Fundamentals * Assessed data
Dynamic Chart
1 week+2.58%
Current month-2.85%
1 month-2.65%
3 months+13.81%
6 months+49.94%
Current year+12.74%
More quotes
1 week
213.50
Extreme 213.5
244.00
1 month
213.50
Extreme 213.5
256.50
Current year
185.20
Extreme 185.2
275.00
1 year
120.00
Extreme 120
275.00
3 years
120.00
Extreme 120
503.50
5 years
120.00
Extreme 120
503.50
10 years
18.00
Extreme 18
503.50
More quotes
Managers TitleAgeSince
Founder 59 94-11-15
Chief Executive Officer 53 21-03-20
Director of Finance/CFO 58 13-05-01
Members of the board TitleAgeSince
Founder 59 94-11-15
Director/Board Member 58 22-05-10
Chairman 62 20-04-22
More insiders
Date Price Change Volume
24-03-28 239 0.00% 1,866
24-03-27 239 +1.06% 14,762
24-03-26 236.5 +6.05% 12,612
24-03-25 223 +2.29% 18,654
24-03-22 218 -6.44% 24,821

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB's product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
239 SEK
Average target price
256.2 SEK
Spread / Average Target
+7.22%
Consensus
  1. Stock
  2. Equities
  3. Stock CellaVision AB - Nasdaq Stockholm